Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

CLLS Cellectis SA

1,90

-0,01 (-0,52%)

19 Okt 2024 - Geschlossen

Verzögert um 15 Minuten

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Article too big to display. Click here to view on the SEC website

Cellectis (NASDAQ:CLLS)
Historical Stock Chart
Von Sep 2024 bis Okt 2024

Click Here for more Cellectis Charts.

Cellectis (NASDAQ:CLLS)
Historical Stock Chart
Von Okt 2023 bis Okt 2024

Click Here for more Cellectis Charts.

News Cellectis SA

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
Mittwoch 11 September 2024 (1 Monat vor) • Edgar (US Regulatory)

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
Dienstag 3 September 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 26 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Montag 26 August 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 7 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Mittwoch 7 August 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 6 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Cellectis Provides Financial Results for the Second Quarter 2024
Dienstag 6 August 2024 (2 Monate vor) • GlobeNewswire Inc.

FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
Donnerstag 1 August 2024 (3 Monate vor) • GlobeNewswire Inc.

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
Donnerstag 25 Juli 2024 (3 Monate vor) • GlobeNewswire Inc.

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
Freitag 28 Juni 2024 (4 Monate vor) • GlobeNewswire Inc.

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
Donnerstag 20 Juni 2024 (4 Monate vor) • GlobeNewswire Inc.

Weitere Cellectis SA News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen